Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Bioorg Med Chem Lett ; 23(12): 3519-22, 2013 Jun 15.
Article in English | MEDLINE | ID: mdl-23668989

ABSTRACT

Five-membered-ring heterocyclic urea mimics have been found to be potent and selective antagonists of the P2Y1 receptor. SAR of the various heterocyclic replacements is presented, as well as side-chain SAR of the more potent thiadiazole ring system which leads to thiadiazole 4c as a new antiplatelet agent.


Subject(s)
Purinergic P2Y Receptor Antagonists/chemistry , Purinergic P2Y Receptor Antagonists/pharmacology , Receptors, Purinergic P2Y1/chemistry , Thiadiazoles/chemistry , Thiadiazoles/pharmacology , Biomimetic Materials/chemistry , Biomimetic Materials/pharmacology , Humans , Kinetics , Protein Binding , Structure-Activity Relationship , Urea/chemistry
2.
Bioorg Med Chem Lett ; 14(17): 4533-7, 2004 Sep 06.
Article in English | MEDLINE | ID: mdl-15357987

ABSTRACT

Bioisosteric replacement studies led to the identification of N-(1-benzo[1,3]dioxol-5-yl-ethyl)-3-(2-chloro-phenyl)-acrylamide ((S)-3) as a highly potent KCNQ2 opener, and 3-(2,6-difluoro-phenyl)-N-[1-(2,3-dihydro-benzofuran-5-yl)-ethyl]-acrylamide ((S)-4), and N-[1-(2,3-dihydro-1H-indol-5-yl)-ethyl]-3-(2-fluoro-phenyl)-acrylamide ((S)-5) as highly efficacious KCNQ2 openers. In contrast, their respective R enantiomers showed significantly less or no appreciable KCNQ2 opener activity even at the highest concentration tested (10 microM). Because of its high potency and moderate efficacy as well as its convenient synthesis, (+/-)-3 was selected as a reference compound for analyzing efficacies of KCNQ openers in electrophysiology studies. Compounds (S)-4 and (S)-5 demonstrated significant activity in reducing neuronal hyperexcitability in rat hippocampal slices. The synthesis and the KCNQ2 opener activity of these acrylamides are described.


Subject(s)
Acrylamides/chemistry , Benzofurans/chemistry , Potassium Channels, Voltage-Gated/metabolism , Acrylamides/pharmacology , Animals , Benzofurans/pharmacology , Cell Line , Dose-Response Relationship, Drug , Hippocampus/drug effects , Hippocampus/metabolism , Humans , KCNQ2 Potassium Channel , Rats
3.
EMBO Rep ; 5(9): 877-82, 2004 Sep.
Article in English | MEDLINE | ID: mdl-15319780

ABSTRACT

The crystal structure of the ligand-binding domain of RARbeta, a suspect tumour suppressor, reveals important features that distinguish it from the two other RAR isotypes. The most striking difference is an extra cavity allowing RARbeta to bind more bulky agonists. Accordingly, we identified a ligand that shows RARbeta selectivity with a 100-fold higher affinity to RARbeta than to alpha or gamma isotypes. The structural differences between the three RAR ligand-binding pockets revealed a rationale explaining how a single retinoid can be at the same time an RARalpha, gamma antagonist and an RARbeta agonist. In addition, we demonstrate how to generate an RARbeta antagonist by gradually modifying the bulkiness of a single substitution. Together, our results provide structural guidelines for the synthesis of RARbeta-selective agonists and antagonists, allowing for the first time to address pharmacologically the tumour suppressor role of RARbeta in vitro and in animal models.


Subject(s)
Receptors, Retinoic Acid/chemistry , Binding Sites , Computational Biology , HeLa Cells , Humans , Ligands , Protein Structure, Tertiary , Receptors, Retinoic Acid/agonists , Receptors, Retinoic Acid/antagonists & inhibitors , Receptors, Retinoic Acid/metabolism , Retinoic Acid Receptor gamma
SELECTION OF CITATIONS
SEARCH DETAIL
...